Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet

Summary

1. To evaluate the effect of S-2367 on body weight when administered following a 6-week placebo lead-in period and then a 54-week 800 kilocalorie deficit reduced calorie diet compared to placebo in healthy obese male and female subjects 2. To evaluate the safety and tolerability of S-2367 during 54 weeks of drug exposure 3. To evaluate the steady-state/trough pharmacokinetics of S-2367

Timeline

Start

2007-06

Primary completion

2008-11

Completion

2009-01

Drugs

Indications